


 Cite this: *RSC Adv.*, 2017, 7, 10432

## Correction: Therapeutic potential of a synthetic FABP4 inhibitor 8g on atherosclerosis in ApoE-deficient mice: the inhibition of lipid accumulation and inflammation

 Heying Pei,<sup>a</sup> Caifeng Xie,<sup>b</sup> Yibin Liu,<sup>a</sup> Mingfeng Shao,<sup>a</sup> Jinying Chen,<sup>a</sup> Dan Li,<sup>a</sup> Liang Ma<sup>c</sup> and Lijuan Chen<sup>\*a</sup>

DOI: 10.1039/c7ra90003a

[www.rsc.org/advances](http://www.rsc.org/advances)

 Correction for 'Therapeutic potential of a synthetic FABP4 inhibitor 8g on atherosclerosis in ApoE-deficient mice: the inhibition of lipid accumulation and inflammation' by Heying Pei *et al.*, *RSC Adv.*, 2016, 6, 52518–52527.

The authors regret that funding details were omitted from the Acknowledgements section of the original article. An acknowledgement of further NSFC funding (ID: 81373260) should be included.

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

<sup>a</sup>State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Keyuan Road 4, Gaopeng Street, Chengdu, 610041, China. E-mail: chenlijuan125@163.com; Fax: +86-28-85164060; Tel: +86-28-85164063

<sup>b</sup>Institute of Translational Medicine, Nanchang University, Nanchang, Jiangxi 330031, P. R. China

<sup>c</sup>Division of Nephrology, Kidney Research Institute, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, China

